结核分枝杆菌潜伏感染诊断方法的新进展

每年有超过8百万人感染结核,其中绝大部分没有发展为活动性结核病,而是表现为潜伏性结核感染。大多数活动性结核病是潜伏感染的结核杆菌重新被激活所致,因此结核潜伏感染者成为结核患者的重要来源。及早诊断和治疗结核潜伏感染者是控制结核传播的最有效手段之一。我们较要综述了目前国内外结核潜伏感染的诊断方法及其新进展。     

Detection of Mycobacterium tuberculosis infection in chacma baboons (Papio ursinus) using the QuantiFERON-TB Gold (In-Tube) assay

Background  Early diagnosis of simian tuberculosis (TB) is vital to prevent transmission of this disease. We evaluated the ability of the QuantiFERON-TB Gold (In-Tube Method) assay (QFG-IT) to detect TB in chacma baboons ( Papio ursinus ).
Methods  Fifty-one baboons were tested using the Tuberculin Skin Test (TST) and the QFG-IT. Baboons testing positive, and animals exposed to infected individuals, were euthanised and subjected to necropsy. Selected tissues were processed for histopathology, mycobacterial culture and genetic speciation.
Results  Tuberculosis was confirmed in one TST positive/QFG-IT positive animal and one TST negative/QFG-IT positive animal. One TST positive/QFG-IT negative animal and five TST negative/QFG-IT negative animals were confirmed uninfected following necropsy.
Conclusion  The QFG-IT correctly detected TB in two baboons, including one TST negative individual and correctly identified six baboons as uninfected, including one TST positive individual. The QFG-IT shows promise as a sensitive, specific test for TB in chacma baboons.     

结核感染T细胞斑点试验联合血清CA125、IP-10对肺结核合并糖尿病的诊断价值

摘要 目的：探讨结核感染T细胞斑点试验（T-SPOT.TB）联合血清糖类抗原125（CA125）、γ干扰素诱导蛋白10（IP-10）对肺结核合并糖尿病的诊断价值。方法：选取2021年1月～2023年1月上海中医药大学附属第七人民医院收治的480例疑似肺结核患者,根据诊断结果分为A组（肺结核合并糖尿病患者）166例、B组（单纯肺结核患者）214例、C组（非结核分枝杆菌感染和非糖尿病患者）100例。所有研究对象均进行T-SPOT.TB,并采用酶联免疫吸附法检测血清CA125、IP-10水平。通过绘制受试者工作特征（ROC）曲线分析T-SPOT.TB联合血清CA125、IP-10水平对肺结核合并糖尿病的诊断价值。结果：A组T-SPOT.TB阳性率低于B组,但高于C组,B组T-SPOT.TB阳性率高于C组（P＜0.05）;A组抗原培养滤液蛋白10（CFP10）、早期分泌性抗原靶蛋白6-kD（ESAT-6）原值高于B组、C组,B组抗原CFP10、抗原ESAT-6原值高于C组（P＜0.05）。A组血清CA125、IP-10水平高于B组和C,B组血清CA125、IP-10水平高于C组（P＜0.05）。ROC曲线分析显示,T-SPOT.TB、CA125、IP-10、T-SPOT.TB+CA125、T-SPOT.TB+IP-10、三项联合诊断肺结核合并糖尿病的曲线下面积（AUC）分别为0.771、0.769、0.779、0.880、0.885、0.937;三项联合诊断肺结核合并糖尿病的AUC大于T-SPOT.TB、CA125、IP-10单独和联合诊断。结论：肺结核合并糖尿病患者T-SPOT.TB阳性率和血清CA125、IP-10水平升高,T-SPOT.TB联合血清CA125、IP-10能提升肺结核合并糖尿病的诊断价值。     

Antigen 85A and mycobacterial DNA‐binding protein 1 are targets of immunoglobulin G in individuals with past tuberculosis

Development of accurate methods for predicting progression of tuberculosis (TB) from the latent state is recognized as vitally important in controlling TB, because a majority of cases develop from latent infections. Past TB that has never been treated has a higher risk of progressing than does latent Mycobacterium tuberculosis infection in patients who have previously received treatment. Antibody responses against 23 kinds of M. tuberculosis proteins in individuals with past TB who had not been medicated were evaluated. These individuals had significantly higher concentrations of antibodies against Antigen 85A and mycobacterial DNA‐binding protein 1 (MDP1) than did those with active TB and uninfected controls. In addition, immunohistochemistry revealed colocalization of tubercle bacilli, antigen 85 and MDP1 inside tuberculous granuloma lesions in an asymptomatic subject, showing that M. tuberculosis in lesions expresses both antigen 85 and MDP1. Our study suggests the potential usefulness of measuring antibody responses to antigen 85A and MDP1 for assessing the risk of TB progression.     

结核感染T细胞斑点试验联合血清ADA、SAA、CA125对活动性肺结核诊断及治疗转归的评估价值

摘要 目的：探讨结核感染T细胞斑点试验（T-SPOT.TB）联合血清腺苷脱氨酶（ADA）、淀粉样蛋白A（SAA）、糖类抗原125（CA125）对活动性肺结核（APTB）诊断及治疗转归的评估价值。方法：选取2021年10月至2022年10月湖南省胸科医院收治的137例APTB患者（APTB组）和80例非APTB患者（对照组）,所有APTB患者接受常规抗结核治疗,根据治疗后转归情况分为转归组（92例）和未转归组（45例）。治疗前进行T-SPOT.TB,并检测血清ADA、SAA、CA125水平。受试者工作特征（ROC）曲线分析T-SPOT.TB联合血清ADA、SAA、CA125诊断APTB和预测治疗转归的效能。结果：APTB组T-SPOT.TB阳性率,血清ADA、SAA、CA125水平高于对照组（P＜0.05）。未转归组T-SPOT.TB阳性率,血清ADA、SAA、CA125水平高于转归组（P＜0.05）。T-SPOT.TB联合血清ADA、SAA、CA125诊断APTB以及预测其治疗转归的曲线下面积（AUC）分别为0.917、0.833,高于单一指标。结论：APTB患者T-SPOT.TB阳性率增加,血清ADA、SAA、CA125水平增高,与抗结核治疗后转归不良有关,T-SPOT.TB联合血清ADA、SAA、CA125在APTB诊断和治疗转归评估中具有较高价值。     

Enterobius vermicularis Infection among Preschool Children: A 12-Year (2008–2019) Survey in Large Cities and Provinces of the Republic of Korea

A 12-year nationwide survey (2008–2019) was performed to investigate the prevalence of Enterobius vermicularis infection among preschool children in Seoul, 4 large cites (Busan, Incheon, Daegu, and Ulsan), and 9 provinces (grouped into 5 localities) in the Republic of Korea (=Korea). The survey was carried out once a year by 16 regional offices of the Korea Association of Health Promotion. The cello-tape perianal swab method (1 smear per child) was applied to detect eggs of E. vermicularis and other helminths. According to the results, the egg positive rate of E. vermicularis infection in 2008–2009 was 1.8–2.0%, but it decreased gradually to 0.6% in 2019 (P<0.05). The prevalence was significantly higher in boys (0.7–5.0%, mean 1.8%) than in girls (0.5–2.8%, mean 1.3%) (P<0.05). The 2 most southern localities, Jeju-do (Province) and Jeolla-do (inclusive of Jeollabuk-do and Jeollanam-do) and a mid-western province, Gyeonggi-do, revealed higher prevalences, whereas Seoul and Gangwon-do showed lower prevalences. The results indicate that a low-grade prevalence of E. vermicularis infection (less than 4%) has been maintained for the recent 12 years among preschool children in Korea. Continuous monitoring of enterobiasis in the child age group is necessary in Korea.     

Evaluation of Two Triple‐Therapy Regimens with Metronidazole or Clarithromycin for the Eradication of H. pylori Infection in Vietnamese Children: a Randomized,Double‐Blind Clinical Trial

Background: Eradication of Helicobacter pylori infection in children in developing countries needs further investigations upon which to base treatment recommendations. The aim of the study was to compare two 2‐week triple therapies in a randomized double‐blind trial. Materials and Methods: In order not to exceed recommended dosages, the 238 H. pylori‐infected children, aged 3 to 15 years (mean 8.6), were divided in two weight categories receiving at weights 13–22 kg: lansoprazole 15 mg once‐daily and amoxicillin 500 mg twice‐daily with metronidazole 250 mg twice‐daily or clarithromycin 250 mg once‐daily; at weights 23–45 kg: lansoprazole 15 mg and amoxicillin 750 mg with metronidazole 500 mg or clarithromycin 250 mg, all administered twice daily. H. pylori status was assessed by culture and a monoclonal‐based antigen‐in‐stool test (Premier Platinum HpSA PLUS) and side effects by structured questionnaires. Results: The overall per‐protocol eradication (n = 233) was similar in the two treatment regimens, 62.1% for the metronidazole and 54.7% for the clarithomycin‐containing therapy. Eradication rate was higher in children ≥ 23 kg (70.9%) than in children < 23 kg (45.7%). In children ≥ 23 kg (n = 117) that received twice‐daily administration of all drugs, efficacy of the methronidazole and clarithromycin‐containing treatments were 69.5% and 72.4%, respectively. Conclusions: The two treatments gave similar eradication rates. Significant differences for both treatments were found by weight, which could be the result of the once‐daily proton pump inhibitor and clarithromycin and/or more antibiotic resistant strains in younger children.